Xenetic Biosciences IncNASDAQ:XBIO
- LAST PRICE3.7700
- TODAY'S CHANGE (%)-0.0800 (-2.0779%)
- Bid / Lots3.7500/ 8
- Ask / Lots3.9500/ 1
- Open / Previous Close3.8000 / 3.8500
- Day Range
- 52 Week Range
- Volume880
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XBIO |
|---|---|---|
| 09:56 ET | 100 | 3.975 |
| 10:17 ET | 122 | 3.77 |
| 10:19 ET | 200 | 3.77 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenetic Biosciences Inc | 5.9M | -1.4x | --- |
OpGen Inc | 5.6M | -0.1x | --- |
Seelos Therapeutics Inc | 4.1M | 0.0x | --- |
Trevena Inc | 7.0M | -0.1x | --- |
Helix BioMedix Inc | 5.2M | -1.5x | --- |
Humanigen Inc | 797.8K | 0.0x | --- |
Company Information
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.
Contact Information
- Headquarters
- 945 Concord St.FRAMINGHAM, MA, United States 01701
- Phone
- 781-778-7720
- Fax
- ---
Executives
- Independent Chairman of the Board
- Adam Logal
- Chief Executive Officer, Director
- Jeffrey Eisenberg
- Chief Financial Officer, Corporate Secretary
- James Parslow
- Chief Scientific Officer
- Curtis Lockshin
- Independent Director
- Grigory Borisenko
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.9M |
|---|---|
Revenue (TTM) | $2.5M |
Shares Outstanding | 1.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.62 |
EPS | $-2.70 |
Book Value | $6.36 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | 2.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -177.79% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
